We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pancreatic Cancer and Venous Thromboembolism.
- Authors
Prouse, Teagan; Mohammad, Mohammad A.; Ghosh, Sonali; Kumar, Narender; Duhaylungsod, Ma. Lorena; Majumder, Rinku; Majumder, Samarpan
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic cancers and is the most fatal of all cancers. The treatment response from combination chemotherapies is far from satisfactory and surgery remains the mainstay of curative strategies. These challenges warrant identifying effective treatments for combating this deadly cancer. PDAC tumor progression is associated with the robust activation of the coagulation system. Notably, cancer-associated thrombosis (CAT) is a significant risk factor in PDAC. CAT is a concept whereby cancer cells promote thromboembolism, primarily venous thromboembolism (VTE). Of all cancer types, PDAC is associated with the highest risk of developing VTE. Hypoxia in a PDAC tumor microenvironment also elevates thrombotic risk. Direct oral anticoagulants (DOACs) or low-molecular-weight heparin (LMWH) are used only as thromboprophylaxis in PDAC. However, a precision medicine approach is recommended to determine the precise dose and duration of thromboprophylaxis in clinical setting.
- Subjects
THROMBOEMBOLISM; PANCREATIC cancer; LOW-molecular-weight heparin; PANCREATIC duct; ORAL medication; ENOXAPARIN; ANTICOAGULANTS
- Publication
International Journal of Molecular Sciences, 2024, Vol 25, Issue 11, p5661
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms25115661